Log in

NASDAQ:IONS - Ionis Pharmaceuticals Stock Price, Forecast & News

$49.41
-0.34 (-0.68 %)
(As of 03/27/2020 04:00 PM ET)
Today's Range
$48.21
Now: $49.41
$50.65
50-Day Range
$41.60
MA: $53.40
$61.73
52-Week Range
$39.32
Now: $49.41
$86.58
Volume995,089 shs
Average Volume1.37 million shs
Market Capitalization$6.88 billion
P/E Ratio23.87
Dividend YieldN/A
Beta2.04
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. It is involved in developing neurology products that include IONIS-HTTRx for Huntington's diseases; and IONIS-SOD1Rx and IONIS-C9Rx for amyotrophic lateral sclerosis and IONIS-MAPTRx for Alzheimer's diseases. The company is also developing severe and rare disease products, such as WAYLIVRA, a treatment for familial chylomicronemia syndrome; WAYLIVRA, a treatment for familial partial lipodystrophy; AKCEA-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; and IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity, IONIS-PKKRx/IONIS-PKK-LRx for hereditary angioedema, and IONIS-ENAC-2.5Rx for cystic fibrosis. In addition, its cardio metabolic and renal drugs include AKCEA-ANGPTL3-LRx for cardio metabolic disorders, IONIS-FXIRx for clotting disorders, AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx for cardiovascular diseases, and IONIS-DGAT2Rx for nonalcoholic steatohepatitis; IONIS-AGT-LRX for the treatment of resistant hyper tension; and IONIS-FXI-LRx for clotting disorders and IONIS-AZ4-2.5-LRx for cardiovascular diseases. Further, the company develops products for oncology that include IONIS-AR-2.5Rx and danvatirsen for cancers; and IONIS-HBVRx and IONIS-HBV-LRx for hepatitis b virus infection, and IONIS-FB-LRx for compliment meditated disease, and IONIS-JBI1-2.5Rx for gastrointestinal autoimmune diseases. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Read More
Ionis Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:IONS
CUSIP46433010
Phone760-931-9200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.12 billion
Cash Flow$2.41 per share
Book Value$11.98 per share

Profitability

Net Income$303.26 million

Miscellaneous

Employees737
Market Cap$6.88 billion
Next Earnings Date5/14/2020 (Estimated)
OptionableOptionable

Receive IONS News and Ratings via Email

Sign-up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter.


Ionis Pharmaceuticals (NASDAQ:IONS) Frequently Asked Questions

How has Ionis Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Ionis Pharmaceuticals' stock was trading at $49.14 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, IONS shares have increased by 0.5% and is now trading at $49.41. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Ionis Pharmaceuticals?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 7 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ionis Pharmaceuticals.

When is Ionis Pharmaceuticals' next earnings date?

Ionis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Ionis Pharmaceuticals.

How were Ionis Pharmaceuticals' earnings last quarter?

Ionis Pharmaceuticals Inc (NASDAQ:IONS) issued its quarterly earnings data on Wednesday, February, 26th. The company reported $1.28 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.91 by $0.37. The company had revenue of $494 million for the quarter, compared to analysts' expectations of $407.05 million. Ionis Pharmaceuticals had a net margin of 26.09% and a return on equity of 22.23%. The firm's revenue for the quarter was up 157.3% on a year-over-year basis. During the same period in the previous year, the firm earned $2.21 earnings per share. View Ionis Pharmaceuticals' earnings history.

What guidance has Ionis Pharmaceuticals issued on next quarter's earnings?

Ionis Pharmaceuticals updated its FY 2020 Pre-Market earnings guidance on Wednesday, February, 26th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $700 million, compared to the consensus revenue estimate of $814.68 million.

What price target have analysts set for IONS?

14 brokers have issued 1 year price targets for Ionis Pharmaceuticals' shares. Their forecasts range from $48.00 to $120.00. On average, they expect Ionis Pharmaceuticals' stock price to reach $74.46 in the next year. This suggests a possible upside of 50.7% from the stock's current price. View analysts' price targets for Ionis Pharmaceuticals.

Has Ionis Pharmaceuticals been receiving favorable news coverage?

News stories about IONS stock have trended somewhat positive on Saturday, according to InfoTrie. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ionis Pharmaceuticals earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days. View the latest news aboutIonis Pharmaceuticals.

Are investors shorting Ionis Pharmaceuticals?

Ionis Pharmaceuticals saw a increase in short interest in the month of February. As of February 14th, there was short interest totaling 9,700,000 shares, an increase of 12.0% from the January 30th total of 8,660,000 shares. Based on an average daily trading volume, of 935,700 shares, the short-interest ratio is presently 10.4 days. Currently, 7.6% of the shares of the stock are short sold. View Ionis Pharmaceuticals' Current Options Chain.

Who are some of Ionis Pharmaceuticals' key competitors?

What other stocks do shareholders of Ionis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), Alibaba Group (BABA), BlackRock (BLK), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Gilead Sciences (GILD), NVIDIA (NVDA), Intercept Pharmaceuticals (ICPT) and Allergan (AGN).

Who are Ionis Pharmaceuticals' key executives?

Ionis Pharmaceuticals' management team includes the following people:
  • Dr. Stanley T. Crooke, Founder, Chairman, CEO & Pres (Age 74)
  • Dr. Brett P. Monia, Founder, COO, Sr. VP of Translational Medicine & Director (Age 58)
  • Ms. Elizabeth L. Hougen, Sr. VP of Fin. & CFO (Age 57)
  • Dr. Richard S. Geary, Sr. VP of Devel. (Age 61)
  • Ms. B. Lynne Parshall, Sr. Strategic Advisor & Director (Age 65)

What is Ionis Pharmaceuticals' stock symbol?

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Who are Ionis Pharmaceuticals' major shareholders?

Ionis Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (14.90%), Baillie Gifford & Co. (6.25%), BVF Inc. IL (1.55%), Renaissance Technologies LLC (1.45%), Geode Capital Management LLC (1.03%) and Norges Bank (0.86%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke. View institutional ownership trends for Ionis Pharmaceuticals.

Which major investors are selling Ionis Pharmaceuticals stock?

IONS stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Marshall Wace North America L.P., Pictet Asset Management Ltd., UBS Group AG, Jacobs Levy Equity Management Inc., Pinnacle Associates Ltd., Bank of America Corp DE, and Rafferty Asset Management LLC. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include B Lynne Parshall, Brett P Monia, Elizabeth L Hougen, Frederick T Muto, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen, and Stanley T Crooke. View insider buying and selling activity for Ionis Pharmaceuticals.

Which major investors are buying Ionis Pharmaceuticals stock?

IONS stock was acquired by a variety of institutional investors in the last quarter, including BVF Inc. IL, Norges Bank, Rockefeller Capital Management L.P., Baillie Gifford & Co., Scout Investments Inc., Renaissance Technologies LLC, Rothschild & Co. Asset Management US Inc., and Sumitomo Mitsui Trust Holdings Inc.. View insider buying and selling activity for Ionis Pharmaceuticals.

How do I buy shares of Ionis Pharmaceuticals?

Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ionis Pharmaceuticals' stock price today?

One share of IONS stock can currently be purchased for approximately $49.41.

How big of a company is Ionis Pharmaceuticals?

Ionis Pharmaceuticals has a market capitalization of $6.88 billion and generates $1.12 billion in revenue each year. The company earns $303.26 million in net income (profit) each year or $2.08 on an earnings per share basis. Ionis Pharmaceuticals employs 737 workers across the globe. View additional information about Ionis Pharmaceuticals.

What is Ionis Pharmaceuticals' official website?

The official website for Ionis Pharmaceuticals is http://www.ionispharma.com/.

How can I contact Ionis Pharmaceuticals?

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at 760-931-9200.


MarketBeat Community Rating for Ionis Pharmaceuticals (NASDAQ IONS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  617 (Vote Outperform)
Underperform Votes:  732 (Vote Underperform)
Total Votes:  1,349
MarketBeat's community ratings are surveys of what our community members think about Ionis Pharmaceuticals and other stocks. Vote "Outperform" if you believe IONS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IONS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/28/2020 by MarketBeat.com Staff

Featured Article: Black Swan

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel